Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1 - PubMed (original) (raw)

. 1991 Sep 15;147(6):1792-6.

Affiliations

PMID: 1716279

Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1

L D Johns et al. J Immunol. 1991.

Abstract

Transforming growth factor-beta 1 (TGF-beta 1) is a multifunctional cytokine with immunosuppressive effects on T cells in vitro. Experimental allergic encephalomyelitis is an archetypal T cell-mediated autoimmune demyelinating disease of the central nervous system that often serves as a model for multiple sclerosis. In vivo administration of TGF-beta 1 into SJL mice was successful in reducing the incidence of clinical disease and the histologic severity of inflammation and demyelination in the brain and spinal cord. Immunohistochemical studies performed on control animals showed that TGF-beta-1, -2, and -3 were present in inflammatory perivascular lesions in the brain. The use of a naturally occurring cytokine with immunoregulatory functions in the treatment of an autoimmune disease is novel. However, potential long term complications of such therapy must be addressed before its use in human autoimmune disease such as multiple sclerosis.

PubMed Disclaimer

Cited by

Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.
Czaja AJ. Czaja AJ. Dig Dis Sci. 2022 Apr;67(4):1163-1186. doi: 10.1007/s10620-021-06968-6. Epub 2021 Apr 9. Dig Dis Sci. 2022. PMID: 33835375 Review.
Astrocyte-Derived TGFβ1 Facilitates Blood-Brain Barrier Function via Non-Canonical Hedgehog Signaling in Brain Microvascular Endothelial Cells.
Fu J, Li L, Huo D, Zhi S, Yang R, Yang B, Xu B, Zhang T, Dai M, Tan C, Chen H, Wang X. Fu J, et al. Brain Sci. 2021 Jan 8;11(1):77. doi: 10.3390/brainsci11010077. Brain Sci. 2021. PMID: 33430164 Free PMC article.
Characterization of Mice with a Platelet-Specific Deletion of the Adapter Molecule ADAP.
Rudolph JM, Guttek K, Weitz G, Meinke CA, Kliche S, Reinhold D, Schraven B, Reinhold A. Rudolph JM, et al. Mol Cell Biol. 2019 Apr 16;39(9):e00365-18. doi: 10.1128/MCB.00365-18. Print 2019 May 1. Mol Cell Biol. 2019. PMID: 30833485 Free PMC article.
Regulation of Lymphatic GM-CSF Expression by the E3 Ubiquitin Ligase Cbl-b.
Peer S, Cappellano G, Hermann-Kleiter N, Albrecht-Schgoer K, Hinterleitner R, Baier G, Gruber T. Peer S, et al. Front Immunol. 2018 Oct 8;9:2311. doi: 10.3389/fimmu.2018.02311. eCollection 2018. Front Immunol. 2018. PMID: 30349541 Free PMC article.
Conjugation of Transforming Growth Factor Beta to Antigen-Loaded Poly(lactide- co-glycolide) Nanoparticles Enhances Efficiency of Antigen-Specific Tolerance.
Casey LM, Pearson RM, Hughes KR, Liu JMH, Rose JA, North MG, Wang LZ, Lei M, Miller SD, Shea LD. Casey LM, et al. Bioconjug Chem. 2018 Mar 21;29(3):813-823. doi: 10.1021/acs.bioconjchem.7b00624. Epub 2017 Nov 30. Bioconjug Chem. 2018. PMID: 29148731 Free PMC article.

Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1 - PubMed (original) (raw)